Developer docs
API playgroundTry for free, no card

Search company profiles

ImpoPharma

Full company profile

uuid00052zp

Namestring
ImpoPharma
Websiteurl
impopharma.com
Company typeenum
Private
Founded yearint
1996
Short descriptiontext

ImpoPharma is a privately held Canadian pharmaceutical services company, founded in 1996 and headquartered in Concord, Canada. It leverages drug development expertise to create new product opportunities for its pharmaceutical industry clients, operating with a small team of 11-50 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersConcord, Canada
HQ citystring
Concord
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pharmaceutical development, drug formulation, contract drug development, pharmaceutical consulting, drug licensing services
Industry1 code
1Primary Care & General Medicine Pharmaceuticals
CodeHLAIAAAAPrimaryYes
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Development Services
Social media profiles1 record
Cost components2 values
Personnel, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ImpoPharma provides drug development expertise that translates into new product opportunities for its clients. Operating as a privately held Canadian pharmaceutical services firm founded in 1996, it supports pharmaceutical companies with development capabilities that enable them to bring new products to market.

Differentiator
Functional benefit
Problem solved
No data
Peers7 records
1Pharmascience
TypeBroad incumbent
Description

Pharmascience is a major Canadian-owned generic and specialty pharmaceutical company that develops, manufactures, and markets pharmaceutical products. It is comparable to ImpoPharma as a fellow Canada-based drug development and commercialization business targeting product opportunities for clients and partners.

2Apotex
TypeBroad incumbent
Description

Apotex is the largest Canadian-based generic pharmaceutical manufacturer, developing and commercializing finished dosage-form products domestically and globally. It is comparable to ImpoPharma because both are Canadian pharma entities focused on turning drug development capability into commercial product portfolios, though Apotex operates at vastly greater scale.

3Cambrex
TypeDirect peer
Description

Cambrex is a CDMO providing small-molecule API development and manufacturing services for pharma clients. It is comparable to ImpoPharma because both operate in the drug development services space, helping clients convert chemical and formulation expertise into new product opportunities.

4Patheon (now Thermo Fisher Pharma Services)
TypeBroad incumbent
Description

Patheon, now part of Thermo Fisher Scientific, is one of the largest global CDMOs offering end-to-end drug development and manufacturing services. It is comparable to ImpoPharma as a scaled-up version of the same drug development services model that the firm offers its clients.

5JAMP Pharma
TypeRegional player
Description

JAMP Pharma is a Canadian pharmaceutical company offering generic, branded, and OTC products developed and manufactured in partnership with global suppliers. It is comparable to ImpoPharma as a Canadian-focused firm whose business centers on developing and bringing new pharmaceutical product opportunities to market.

6AAI Pharma Services
TypeDirect peer
Description

AAI Pharma Services (AAI/Cambrex) provides contract drug development, analytical, and manufacturing services from pre-formulation through commercial supply. It is comparable to ImpoPharma as a similarly positioned drug development services firm whose core business is converting client product opportunities into commercialized pharmaceuticals.

7Taro Pharmaceutical Industries
TypeDirect peer
Description

Taro Pharmaceutical develops, manufactures, and markets generic and specialty pharmaceutical products, including prescription and OTC formulations. It is comparable to ImpoPharma because both focus on leveraging drug development expertise to create new pharmaceutical product opportunities for healthcare markets.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImpoPharma

Pharmaceutical Development Servicesimpopharma.com

ImpoPharma is a privately held Canadian pharmaceutical services company, founded in 1996 and headquartered in Concord, Canada. It leverages drug development expertise to create new product opportunities for its pharmaceutical industry clients, operating with a small team of 11-50 employees.

ImpoPharma firmographics

Firmographics
Name
ImpoPharma
Website
https://impopharma.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
ImpoPharma is a privately held Canadian pharmaceutical services company, founded in 1996 and headquartered in Concord, Canada. It leverages drug development expertise to create new product opportunities for its pharmaceutical industry clients, operating with a small team of 11-50 employees.
Ownership category
akta.pro rank

ImpoPharma industry classification

Industry
Product category
Pharmaceutical Development Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

  • Pharmaceutical development
  • Drug formulation
  • Contract drug development
  • Pharmaceutical consulting
  • Drug licensing services

Where ImpoPharma is headquartered

Location

Headquarters

HQ city
Concord
HQ country
Canada
HQ region
North America

Markets served

ImpoPharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D

ImpoPharma product offering

Product offering

Core offering

ImpoPharma provides drug development expertise that translates into new product opportunities for its clients. Operating as a privately held Canadian pharmaceutical services firm founded in 1996, it supports pharmaceutical companies with development capabilities that enable them to bring new products to market.

Differentiator

Problem solved

Functional benefit

Companies that use ImpoPharma

Customer profile

Ideal customer profiles1 record

ImpoPharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ImpoPharma competitors and assessment

Company assessment

Broad incumbents

  • Pharmascience: Pharmascience is a major Canadian-owned generic and specialty pharmaceutical company that develops, manufactures, and markets pharmaceutical products. It is comparable to ImpoPharma as a fellow Canada-based drug development and commercialization business targeting product opportunities for clients and partners.
  • Apotex: Apotex is the largest Canadian-based generic pharmaceutical manufacturer, developing and commercializing finished dosage-form products domestically and globally. It is comparable to ImpoPharma because both are Canadian pharma entities focused on turning drug development capability into commercial product portfolios, though Apotex operates at vastly greater scale.
  • Patheon (now Thermo Fisher Pharma Services): Patheon, now part of Thermo Fisher Scientific, is one of the largest global CDMOs offering end-to-end drug development and manufacturing services. It is comparable to ImpoPharma as a scaled-up version of the same drug development services model that the firm offers its clients.

Direct peers

  • Cambrex: Cambrex is a CDMO providing small-molecule API development and manufacturing services for pharma clients. It is comparable to ImpoPharma because both operate in the drug development services space, helping clients convert chemical and formulation expertise into new product opportunities.
  • AAI Pharma Services: AAI Pharma Services (AAI/Cambrex) provides contract drug development, analytical, and manufacturing services from pre-formulation through commercial supply. It is comparable to ImpoPharma as a similarly positioned drug development services firm whose core business is converting client product opportunities into commercialized pharmaceuticals.
  • Taro Pharmaceutical Industries: Taro Pharmaceutical develops, manufactures, and markets generic and specialty pharmaceutical products, including prescription and OTC formulations. It is comparable to ImpoPharma because both focus on leveraging drug development expertise to create new pharmaceutical product opportunities for healthcare markets.

Regional players

  • JAMP Pharma: JAMP Pharma is a Canadian pharmaceutical company offering generic, branded, and OTC products developed and manufactured in partnership with global suppliers. It is comparable to ImpoPharma as a Canadian-focused firm whose business centers on developing and bringing new pharmaceutical product opportunities to market.

Market position

Customer concentration

ImpoPharma social profiles

Digital presence

ImpoPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImpoPharma leadership team

Management profile

Number of profiles

Profiles1 record

ImpoPharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImpoPharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImpoPharma

What does ImpoPharma do?

ImpoPharma provides drug development expertise that translates into new product opportunities for its clients. Operating as a privately held Canadian pharmaceutical services firm founded in 1996, it supports pharmaceutical companies with development capabilities that enable them to bring new products to market.

When was ImpoPharma founded?

ImpoPharma was founded in 1996. It employs 11 to 50 people.

Where is ImpoPharma based?

ImpoPharma is headquartered in Concord, Canada, in the North America region.

Who are ImpoPharma's main competitors?

Broad incumbents on record are Pharmascience, Apotex and Patheon (now Thermo Fisher Pharma Services). Direct peers are Cambrex, AAI Pharma Services and Taro Pharmaceutical Industries. JAMP Pharma is listed as a regional player.

Does ImpoPharma have an API?

No public API is recorded for ImpoPharma.

What industry is ImpoPharma in?

ImpoPharma's product category is Pharmaceutical Development Services. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireImpopharma Launches New Corporate Logo and WebsiteImpopharma, Inc. announced the launch of a new corporate logo and enhanced website as part of a strategic re-branding effort to reflect the company's growth and positioning in the specialty pharmaceutical sector. The Concord, Ontario-based company specializes in pulmonary and nasal drug delivery products. The re-branding is intended to strengthen relationships with clients and partners while articulating their specialized development and analytical capabilities.PR NewswireImpopharma Inc. Strengthens Management Team and Board of DirectorsImpopharma Inc. announced organizational changes including the appointment of David Mayers as Chief Operating Officer and member of the Board of Directors, replacing co-founder Hanna Piskorz who retired. The company also hired Dr. David Brown as Senior Director of R&D from Teva Ltd and appointed Wayne Kreppner to the Board, while Lloyd Segal stepped down as an independent director. Mayers brings 27 years of pharmaceutical industry experience including leadership roles at WellSpring Pharma Services and Purdue Pharma, and the company stated these changes will help build out its future operations.PR NewswireBreckenridge Pharmaceutical, Inc. and Impopharma, Inc. enter into licensing agreementBreckenridge Pharmaceutical, Inc. has entered into a licensing agreement with Impopharma, Inc. to commercialize a generic corticosteroid product in the U.S. market. Breckenridge will exclusively market the product while Impopharma serves as the manufacturer of the pending ANDA. The product is projected to have generic sales exceeding $25 million.PR NewswireImpopharma Inc. and Breckenridge Pharmaceutical Inc. Enter Into an Asset-Purchase Agreement to Commercialize the Generic Version of a Leading Corticosteroid Product Upon FDA ApprovalImpopharma Inc. announced it has entered into an asset purchase, license, and commercialization agreement with Breckenridge Pharmaceutical, Inc., under which Breckenridge acquired the ANDA for a generic version of a leading anti-inflammatory corticosteroid product. Upon FDA approval, Breckenridge will market and distribute the product in the U.S. market, with the ANDA filing already accepted for review with a GDUFA goal for late 2017.